64 related articles for article (PubMed ID: 30700638)
1. Pulmonary Arterial Hypertension with Features of Venous Involvement: A Detective's Task.
Cazeiro DI; Plácido R; Raposo MA; Brito J; Borba A; Guimarães T; Pinto E; Freitas P; Pinto FJ
Arq Bras Cardiol; 2024; 121(4):e20230565. PubMed ID: 38695472
[TBL] [Abstract][Full Text] [Related]
2. Lung transplantation in primary pulmonary arterial hypertension and pulmonary venous hypertension.
Sainathan S; Ryan J; Mullinari L; Sanchez P
Clin Transplant; 2024 Jan; 38(1):e15158. PubMed ID: 37788166
[TBL] [Abstract][Full Text] [Related]
3. Functional validation of EIF2AK4 (GCN2) missense variants associated with pulmonary arterial hypertension.
Emanuelli G; Zhu J; Li W; Morrell NW; Marciniak SJ
Hum Mol Genet; 2024 May; ():. PubMed ID: 38776952
[TBL] [Abstract][Full Text] [Related]
4. Dyspnoea and diffuse pulmonary nodules in a patient with pulmonary veno-occlusive disease: a case report and literature review.
He Y; Xie M; Liu X
J Int Med Res; 2021 Jan; 49(1):300060520986689. PubMed ID: 33478317
[TBL] [Abstract][Full Text] [Related]
5. Acute venodilation properties of low-dose intravenous nitroglycerine in pulmonary veno-occlusive disease: a case report.
Maruyama H; Sakai S; Suzuki S
Eur Heart J Case Rep; 2023 Aug; 7(8):ytad365. PubMed ID: 37575546
[TBL] [Abstract][Full Text] [Related]
6. Patient-specific and gene-corrected induced pluripotent stem cell-derived endothelial cells elucidate single-cell phenotype of pulmonary veno-occlusive disease.
Ma B; Li T; Li W; Yang H; Zeng Q; Pan Z; Wang K; Chen Q; Xiong C; Zhou Z
Stem Cell Reports; 2022 Dec; 17(12):2674-2689. PubMed ID: 36400028
[TBL] [Abstract][Full Text] [Related]
7. The Platelet-Derived Growth Factor Pathway in Pulmonary Arterial Hypertension: Still an Interesting Target?
Solinc J; Ribot J; Soubrier F; Pavoine C; Dierick F; Nadaud S
Life (Basel); 2022 Apr; 12(5):. PubMed ID: 35629326
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary veno-occlusive disease in childhood-a rare disease not to be missed.
Pfluger M; Humpl T
Cardiovasc Diagn Ther; 2021 Aug; 11(4):1070-1079. PubMed ID: 34527533
[TBL] [Abstract][Full Text] [Related]
9. COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure.
Marchetti M
Ann Hematol; 2020 Aug; 99(8):1701-1707. PubMed ID: 32583086
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary capillary haemangiomatosis: a distinct entity?
Weatherald J; Dorfmüller P; Perros F; Ghigna MR; Girerd B; Humbert M; Montani D
Eur Respir Rev; 2020 Jun; 29(156):. PubMed ID: 32461209
[TBL] [Abstract][Full Text] [Related]
11. ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs.
Reinero C; Visser LC; Kellihan HB; Masseau I; Rozanski E; Clercx C; Williams K; Abbott J; Borgarelli M; Scansen BA
J Vet Intern Med; 2020 Mar; 34(2):549-573. PubMed ID: 32065428
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of long-term imatinib therapy for patients with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis.
Ogawa A; Miyaji K; Matsubara H
Respir Med; 2017 Oct; 131():215-219. PubMed ID: 28947033
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology.
Montani D; Achouh L; Dorfmüller P; Le Pavec J; Sztrymf B; Tchérakian C; Rabiller A; Haque R; Sitbon O; Jaïs X; Dartevelle P; Maître S; Capron F; Musset D; Simonneau G; Humbert M
Medicine (Baltimore); 2008 Jul; 87(4):220-233. PubMed ID: 18626305
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Hemodynamic Responses to Imatinib in Pulmonary Veno-Occlusive Disease/Pulmonary Capillary Hemangiomatosis: A Retrospective Pilot Study of Five Cases and Review of the Literature.
Nakamura J; Tsujino I; Shima H; Nakaya T; Sugimoto A; Sato T; Watanabe T; Ohira H; Suzuki M; Tsuneta S; Hisada R; Kato M; Konno S
Am J Cardiovasc Drugs; 2023 May; 23(3):329-338. PubMed ID: 36995544
[TBL] [Abstract][Full Text] [Related]
15. Good response to pulmonary arterial hypertension-targeted therapy in 2 pulmonary veno-occlusive disease patients: A case report.
Zhang L; Wang Y; Zhang R
Medicine (Baltimore); 2021 Oct; 100(41):e27334. PubMed ID: 34731104
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary veno-occlusive disease: a rare cause of pulmonary hypertension in systemic sclerosis. Case presentation and review of the literature .
Daraban AM; Enache R; Predescu L; Platon P; Constantinescu T; Mihai C; Coman IM; Ginghina C; Jurcuţ R
Rom J Intern Med; 2015; 53(2):175-83. PubMed ID: 26402988
[TBL] [Abstract][Full Text] [Related]
17. Beneficial Effects of Imatinib in a Patient with Suspected Pulmonary Veno-Occlusive Disease.
Sato H; Sugimura K; Miura M; Konno R; Kozu K; Yaoita N; Shimizu T; Yamamoto S; Aoki T; Tatebe S; Satoh K; Shimokawa H
Tohoku J Exp Med; 2019 Feb; 247(2):69-73. PubMed ID: 30700638
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
